Clinical trials: Residual
Non-small Cell Lung Cancer, Minimal Residual Disease
Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation
To study the efficacy of sintilimab combined with anlotinib for perioperative non-small cell lung cancer. To explore the clearance effect of sintilimab combined with anlotinib for postoperative adjuvant therapy based on…
- Conditions
- Non-small Cell Lung Cancer, Minimal Residual Disease, Immunotherapy, Anti-angiogenesis
- Trial name
- NCT05460195
- Testing
- sintilimab combined with anlotinib, sintilimab monotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shanghai Chest Hospital
Kidney Failure, Chronic
Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan
Angiotensin II receptor blockers (ARB) are known to preserve kidney function among patients with kidney diseases and reduced renal function, but not among haemodialysis patients.
- Trial name
- SAFIR (NCT00791830)
- Testing
- Irbesartan
- Where
- 6 sites in Denmark
- Volunteers
- 82 people
- Sponsor
- University of Aarhus
Prostate Cancer
Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy
Prostate cancer is the most common solid cancer affecting male patients worldwide. When diagnosed early, it can usually be cured with surgery (radical prostatectomy), but this procedure is associated with side effects such as…
- Trial name
- NCT06398470
- Testing
- NeuroSAFE procedure, LaserSAFE procedure
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- University College, London
B-Cell Acute Lymphoblastic Leukemia
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD…
- Trial name
- CASSIOPEIA (NCT03876769)
- Testing
- CTL019
- Where
- 43 sites in United States, Belgium and 9 more
- Volunteers
- 121 people
- Sponsor
- Novartis Pharmaceuticals
Postoperative Residual Curarization, Airway Obstruction on Anaesthetic Emergence
Measuring Upper Airway Cross Sectional Areas During Residual Neuromuscular Blockade and After Reserval
In our study, the investigators sought to answer the question of how the retroglossal pharyngeal areas measured after extubation of patients compare to baseline (before muscle relaxation) values.
- Trial name
- NCT06544980
- Where
- Hungary
- Volunteers
- 20 people
- Sponsor
- Tamas Vegh, MD
Pituitary Neoplasms, Pituitary Adenoma
Hypofractionated Radiosurgery to Treat Residual/Recurrent Non Secreting Pituitary Adenoma (HYPOADENO)
Single session stereotactic radiosurgery (SRS) is commonly used for patients with non-functioning adenomas. However the SRS can be limited by the proximity of the tumor with the surrounding critical structures (i.e., the optic…
- Trial name
- HYPOADENO (NCT06826170)
- Testing
- hypofractionated radiosurgery
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Breast Neoplasms
Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer
This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing.
- Trial name
- SCAN-B (NCT02306096)
- Where
- 10 sites in Sweden
- Volunteers
- 20,000 people
- Sponsor
- Lund University
CML, Chronic Phase
Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study
To assess the efficacy of inecalcitol in combination with imatinib in CML patients with molecular residual disease on imatinib monotherapy.
- Trial name
- ICT10 (NCT02949570)
- Testing
- Inecalcitol
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Hybrigenics Corporation
Leukemia, Lymphocytic, Acute, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT
The clinical study of CART19 Cells treatment for MRD of B Cell Malignancies and then auto-HSCT
- Conditions
- Leukemia, Lymphocytic, Acute, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell
- Trial name
- NCT03685786
- Testing
- CART19 cell and auto-HSCT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Second People's Hospital
Mycoses
Validation of Pathologic Diagnosis of Invasive Fungal Infection by Molecular Method
1. Isolate fungal DNA(Deoxyribonucleic acid) from paraffin-fixed tissue specimens to distinguish and compare Aspergillus species to the existing optical pathological diagnosis. 2. PCR(polymerase chain reaction) validation. 3.
- Trial name
- NCT02676570
- Volunteers
- 50 people
- Sponsor
- Seoul St. Mary's Hospital
Hip Osteoarthritis, Muscle Weakness
The Role of Surgical Approach on Residual Limping After Total Hip Arthroplasty
Residual limping after total hip arthroplasty is empirically associated with the use of lateral approach but has been reported in litterature even with the use of posterior approach.
- Conditions
- Hip Osteoarthritis, Muscle Weakness, Muscle Atrophy, Muscle Injury
- Trial name
- HSS (NCT05216666)
- Testing
- Lateral approach, Posterior approach
- Where
- Sweden
- Volunteers
- 580 people
- Sponsor
- Sahlgrenska University Hospital
Resectable Colorectal Carcinoma, Stage II Colorectal Cancer AJCC v8
Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
This clinical trial compares minimal residual disease (MRD) testing with the Haystack blood test (assay) to the Signatera® assay for the early detection of the cancer returning (cancer recurrence) in patients with stage II-IV…
- Conditions
- Resectable Colorectal Carcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT07125729
- Testing
- Biospecimen Collection, cfDNA or ctDNA Measurement, Electronic Health Record Review
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- City of Hope Medical Center
Classical Hodgkin Lymphoma
European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma
Classical Hodgkin lymphoma (cHL) accounts for 15% of all cases of cancer in children and adolescents and represents the first cause of cancer during adolescence.
- Trial name
- EURHOLY (NCT07356882)
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non Small Cell Lung Cancer, Stage III Lung Cancer
Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC
This study investigates whether postoperative radiotherapy (PORT) improves outcomes for patients with stage III non-small cell lung cancer (NSCLC) who have residual disease after neoadjuvant chemo-immunotherapy and surgery.
- Trial name
- RESCUE (NCT06878274)
- Testing
- Post-operative radiotherapy
- Where
- Canada
- Volunteers
- 118 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Aortic Aneurysm, Aortic Aneurysm, Thoracic
Saline Flush to Reduce the Amount of Residual Air Inside a Stentgraft Delivery System
Non-randomized studies have shown that de-airing of the delivery system with an increased volume of saline may be associated to a decrease in periprocedural stroke during thoracic endovascular aortic repair.
- Conditions
- Aortic Aneurysm, Aortic Aneurysm, Thoracic, Aortic Diseases, Aortic Arch Aneurysm
- Trial name
- SAFRANE (NCT04909190)
- Testing
- Increased saline flush volume
- Where
- Hungary
- Volunteers
- 30 people
- Sponsor
- Semmelweis University Heart and Vascular Center
Barrett's Esophagus
Cryo Balloon for Residual Barrett's Esophagus
This study is being done to see if treating residual Barrett's Esophagus after previously having undergone Radiofrequency ablation or Endoscopic Mucosal resection can be eliminated with focal cryotherapy.
- Trial name
- Cryoballoon (NCT02230410)
- Testing
- CryoBalloon Focal Ablation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Breast Neoplasm, Neoplasm Metastasis
Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy
The ability of chemotherapy to cure cancer, including breast cancer, has been limited by drug resistant residual tumor cells remaining after chemotherapy that generally result in relapse.
- Trial name
- NCT00001440
- Testing
- Autologous T cells, Interleukin-2
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Minimal Residual Disease
Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients
This is a interventional, transplantation study. The procedure under study is the infusion of alloreactive NK cells in adult AML patients, eligible for ASCT, who achieved CR after conventional chemotherapy, but harbor…
- Conditions
- Acute Myeloid Leukemia, Minimal Residual Disease, Natural Killer Cell
- Trial name
- NCT06885476
- Testing
- Infusion of alloreactive NK cells
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Acute Coronary Syndrome, HIV
EValuation of REsidual Platelet REactivity After Acute Coronary Syndrome (ST+/ST-) in HIV
Elevated on-treatment platelet reactivity is an independent risk factor of major adverse cardiovascular events following percutaneous coronary intervention or ACS.
- Trial name
- EVERE2ST-HIV (NCT02380391)
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Saint Antoine University Hospital
Newly Diagnosed Triple-negative Breast Cancer
A Multicenter, Randomized, Controlled Phase III Clinical Trial on Adjuvant Intensified Therapy for Patients With Residual Disease After Neoadjuvant Treatment for Triple-negative Breast Cancer
This study is a multicenter, randomized controlled phase III clinical trial. The aim of this study is to observe the efficacy and safety of PD-1 inhibitors combined with capecitabine, PD-1 inhibitors alone, or capecitabine alone…
- Trial name
- CREATE (NCT07869628)
- Testing
- Capecitabine and PD-1 inhibitor, PD-1 inhibitor, Capecitabine
- Volunteers
- 852 people
- Sponsor
- Shandong Cancer Hospital and Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.